{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T00:33:34Z","timestamp":1793234014131,"version":"4.5.0"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:00:00Z","timestamp":1789603200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicalnutritionjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Nutrition"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.clnu.2026.106800","type":"journal-article","created":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T23:25:27Z","timestamp":1789773927000},"page":"106800","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["A multidisciplinary nutritional-behavioral intervention improves weight loss and liver-related outcomes in patients with metabolic dysfunction-associated steatotic liver disease: A randomized controlled trial"],"prefix":"10.1016","volume":"66","author":[{"given":"Marcello","family":"Dallio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2970-9019","authenticated-orcid":false,"given":"Mario","family":"Romeo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiammetta","family":"Di Nardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmine","family":"Napolitano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annachiara","family":"Coppola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Mazzarella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Vaia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Basile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Federico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clnu.2026.106800_bib1","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1002\/ueg2.70072","article-title":"The rising global burden of MASLD and other metabolic diseases (2000-2021)","volume":"13","author":"Danpanichkul","year":"2025","journal-title":"United Eur Gastroenterol J"},{"key":"10.1016\/j.clnu.2026.106800_bib2","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1111\/apt.70020","article-title":"Addressing the high and rising global burden of metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH): from the growing prevalence to payors' perspective","volume":"61","author":"Younossi","year":"2025","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.clnu.2026.106800_bib3","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1111\/apt.70078","article-title":"Editorial: chrononutrition and MASLD \u2014its about time (restricted feeding)","volume":"61","author":"Mohr","year":"2025","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.clnu.2026.106800_bib4","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1111\/apt.18451","article-title":"Meta-analysis: global prevalence and mortality of cirrhosis in metabolic dysfunction-associated steatotic liver disease","volume":"61","author":"Owrangi","year":"2025","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.clnu.2026.106800_bib5","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1016\/j.jhep.2023.08.030","article-title":"Endocrine aspects of metabolic dysfunction-associated steatotic liver disease (MASLD): beyond insulin resistance","volume":"79","author":"Hutchison","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.clnu.2026.106800_bib6","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2024.1433857","article-title":"Systemic impacts of metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) on heart, muscle, and kidney related diseases","volume":"12","author":"Sandireddy","year":"2024","journal-title":"Front Cell Dev Biol"},{"key":"10.1016\/j.clnu.2026.106800_bib7","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1136\/gutjnl-2023-330595","article-title":"MASLD: a systemic metabolic disorder with cardiovascular and malignant complications","volume":"73","author":"Targher","year":"2024","journal-title":"Gut"},{"key":"10.1016\/j.clnu.2026.106800_bib8","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.jhep.2024.08.024","article-title":"Frailty and risk of metabolic dysfunction-associated steatotic liver disease and other chronic liver diseases","volume":"82","author":"Zhong","year":"2025","journal-title":"J Hepatol"},{"key":"10.1016\/j.clnu.2026.106800_bib9","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1002\/ueg2.12525","article-title":"Therapeutic management of metabolic dysfunction associated steatotic liver disease","volume":"12","author":"Zeng","year":"2024","journal-title":"United Eur Gastroenterol J"},{"key":"10.1016\/j.clnu.2026.106800_bib10","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1056\/NEJMoa2413258","article-title":"Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis","volume":"392","author":"Sanyal","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clnu.2026.106800_bib11","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2309000","article-title":"A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis","volume":"390","author":"Harrison","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clnu.2026.106800_bib12","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1016\/S0140-6736(25)00509-4","article-title":"Semaglutide and walking capacity in people with symptomatic peripheral artery disease and type 2 diabetes (STRIDE): a phase 3b, double-blind, randomised, placebo-controlled trial","volume":"405","author":"Bonaca","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.clnu.2026.106800_bib13","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.jhep.2024.04.031","article-title":"European association for the study of diabetes (EASD), european association for the study of obesity (EASO). EASL-EASD-EASO clinical practice guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)","volume":"81","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.clnu.2026.106800_bib14","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/apt.70169","article-title":"Association between volume, intensity and rhythm of physical activity measured by accelerometer and risk of all-cause and cause-specific mortality in individuals with MASLD","volume":"62","author":"Peng","year":"2025","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.clnu.2026.106800_bib15","doi-asserted-by":"crossref","DOI":"10.3389\/fnut.2024.1421386","article-title":"Evidence summary of lifestyle interventions in adults with metabolic dysfunction-associated steatotic liver disease","volume":"11","author":"Chen","year":"2025","journal-title":"Front Nutr"},{"key":"10.1016\/j.clnu.2026.106800_bib16","doi-asserted-by":"crossref","DOI":"10.1038\/srep36783","article-title":"Long-term lifestyle interventions in middle-aged and elderly men with nonalcoholic fatty liver disease: a randomized controlled trial","volume":"6","author":"Dong","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.clnu.2026.106800_bib17","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1093\/nutrit\/nuaf001","article-title":"Nutritional and psychological support as a multidisciplinary coordinated approach in the management of chronic liver disease: a scoping review","volume":"83","author":"Romeo","year":"2025","journal-title":"Nutr Rev"},{"key":"10.1016\/j.clnu.2026.106800_bib18","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1017\/S0033291720005292","article-title":"The evidence for cognitive behavioural therapy in any condition, population or context: a meta-review of systematic reviews and panoramic meta-analysis","volume":"51","author":"Fordham","year":"2021","journal-title":"Psychol Med"},{"key":"10.1016\/j.clnu.2026.106800_bib19","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1016\/j.jhep.2023.06.003","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"79","author":"Rinella","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.clnu.2026.106800_bib20","doi-asserted-by":"crossref","first-page":"58","DOI":"10.3390\/livers5040058","article-title":"From \u201cMAFLD\u201d to \u201cMASLD\u201d: was this revolution worth it? A head-to-head comparison of MAFLD and MASLD criteria in estimating liver disease progression and cardiovascular risk in real life","volume":"5","author":"Dallio","year":"2025","journal-title":"Liver"},{"key":"10.1016\/j.clnu.2026.106800_bib21","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25105203","article-title":"Drug-induced fatty liver disease (DIFLD): a comprehensive analysis of clinical, biochemical, and histopathological data for mechanisms identification and consistency with current adverse outcome pathways","volume":"25","author":"L\u00f3pez-Pascual","year":"2024","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.clnu.2026.106800_bib22","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1111\/j.1360-0443.1993.tb02093.x","article-title":"Development of the alcohol use disorders identification test (AUDIT): WHO collaborative project on early detection of persons with harmful alcohol Consumption--II","volume":"88","author":"Saunders","year":"1993","journal-title":"Addiction"},{"key":"10.1016\/j.clnu.2026.106800_bib23","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-025-15425-7","article-title":"HOMA-IR, an independent predictor of advanced liver fibrosis in metabolic-dysfunction associated fatty liver disease: a cross-sectional study in Egyptian patients","volume":"15","author":"Fouad","year":"2025","journal-title":"Sci Rep"},{"key":"10.1016\/j.clnu.2026.106800_bib24","article-title":"Atherosclerotic cardiovascular disease risk assessment: an American society for preventive cardiology clinical practice statement","volume":"10","author":"Wong","year":"2022","journal-title":"Am J Prev Cardiol"},{"key":"10.1016\/j.clnu.2026.106800_bib25","doi-asserted-by":"crossref","first-page":"CR735","DOI":"10.12659\/MSM.883601","article-title":"The BARD score and the NAFLD fibrosis score in the assessment of advanced liver fibrosis in nonalcoholic fatty liver disease","volume":"18","author":"Cicho\u017c-Lach","year":"2012","journal-title":"Med Sci Monit"},{"key":"10.1016\/j.clnu.2026.106800_bib26","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1001\/jamainternmed.2025.1809","article-title":"Adverse liver outcomes, cardiovascular events, and mortality in steatotic liver disease","volume":"185","author":"Ochoa-Allemant","year":"2025","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.clnu.2026.106800_bib27","doi-asserted-by":"crossref","DOI":"10.3390\/ijms26020761","article-title":"FLAME: training and validating a newly conceived model incorporating Alpha-Glutathione-S-Transferase serum levels for predicting advanced hepatic fibrosis and acute cardiovascular events in metabolic Dysfunction-associated steatotic liver disease (MASLD)","volume":"26","author":"Dallio","year":"2025","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.clnu.2026.106800_bib28","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1136\/gutjnl-2023-331003","article-title":"Metabolic dysfunction-associated steatotic liver disease and risk of cardiovascular disease","volume":"73","author":"Lee","year":"2024","journal-title":"Gut"},{"key":"10.1016\/j.clnu.2026.106800_bib29","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1001\/jama.2018.6360","article-title":"Randomization in clinical trials: permuted blocks and stratification","volume":"319","author":"Broglio","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.clnu.2026.106800_bib30","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1002\/hep.25993","article-title":"Determination of reliability criteria for liver stiffness evaluation by transient elastography","volume":"57","author":"Boursier","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.clnu.2026.106800_bib31","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1053\/j.gastro.2019.01.042","article-title":"Accuracy of FibroScan controlled attenuation parameter and liver stiffness measurement in assessing steatosis and fibrosis in patients with nonalcoholic fatty liver disease","volume":"156","author":"Eddowes","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.clnu.2026.106800_bib32","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1093\/ajcn\/82.1.163","article-title":"Diet-quality scores and plasma concentrations of markers of inflammation and endothelial dysfunction","volume":"82","author":"Fung","year":"2005","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.clnu.2026.106800_bib33","doi-asserted-by":"crossref","DOI":"10.1186\/1479-5868-8-115","article-title":"Validity of the international physical activity questionnaire short form (IPAQ-SF): a systematic review","volume":"8","author":"Lee","year":"2011","journal-title":"Int J Behav Nutr Phys Activ"},{"key":"10.1016\/j.clnu.2026.106800_bib34","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1037\/0003-066X.47.9.1102","article-title":"In search of how people change. Applications to addictive behaviors","volume":"47","author":"Prochaska","year":"1992","journal-title":"Am Psychol"},{"key":"10.1016\/j.clnu.2026.106800_bib35","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1080\/03007995.2018.1512478","article-title":"Development of the medication adherence estimation and differentiation scale (MEDS)","volume":"35","author":"Athavale","year":"2019","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.clnu.2026.106800_bib36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/17437199.2016.1190659","article-title":"Identifying content-based and relational techniques to change behaviour in motivational interviewing","volume":"11","author":"Hardcastle","year":"2017","journal-title":"Health Psychol Rev"},{"key":"10.1016\/j.clnu.2026.106800_bib37","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1111\/dom.12195","article-title":"The potential for motivational interviewing to improve outcomes in the management of diabetes and obesity in paediatric and adult populations: a clinical review","volume":"16","author":"Christie","year":"2014","journal-title":"Diabetes Obes Metabol"},{"key":"10.1016\/j.clnu.2026.106800_bib38","doi-asserted-by":"crossref","DOI":"10.1136\/gutjnl-2025-IDDF.143","article-title":"Normal-weight MASLD: reclassification, characteristics, and adverse liver outcomes across diverse populations","volume":"32","author":"Song","year":"2025","journal-title":"Clin Mol Hepatol"},{"key":"10.1016\/j.clnu.2026.106800_bib39","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1038\/s41430-020-00778-1","article-title":"Effects of dietary macronutrients on liver fat content in adults: a systematic review and meta-analysis of randomized controlled trials","volume":"75","author":"Winters-van Eekelen","year":"2021","journal-title":"Eur J Clin Nutr"},{"key":"10.1016\/j.clnu.2026.106800_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.arcmed.2025.103306","article-title":"Phase Angle\/C-reactive protein-index as a novel combined tool for predicting liver-related hospitalizations in MASLD-decompensated cirrhosis","volume":"56","author":"Dallio","year":"2025","journal-title":"Arch Med Res"},{"key":"10.1016\/j.clnu.2026.106800_bib41","doi-asserted-by":"crossref","DOI":"10.1038\/s41387-024-00294-2","article-title":"The influence of acute lifestyle changes on NAFLD evolution in a multicentre cohort: a matter of body composition","volume":"14","author":"Dallio","year":"2024","journal-title":"Nutr Diabetes"},{"key":"10.1016\/j.clnu.2026.106800_bib42","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-025-94234-4","article-title":"Early stage of metabolic dysfunction associated steatotic liver disease disrupts circadian rhythm and induces neuroinflammation in rats","volume":"15","author":"Graindorge","year":"2025","journal-title":"Sci Rep"},{"key":"10.1016\/j.clnu.2026.106800_bib43","doi-asserted-by":"crossref","first-page":"195","DOI":"10.3949\/ccjm.77a.09064","article-title":"When and how to evaluate mildly elevated liver enzymes in apparently healthy patients","volume":"77","author":"Aragon","year":"2010","journal-title":"Cleve Clin J Med"},{"key":"10.1016\/j.clnu.2026.106800_bib44","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/d41586-024-03030-z","article-title":"Yo-yo dieting accelerates cardiovascular disease by reprogramming the immune system","volume":"634","author":"Rader","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.clnu.2026.106800_bib45","doi-asserted-by":"crossref","DOI":"10.3892\/br.2025.2036","article-title":"Impact of weight loss and lifestyle modifications on liver fibrosis in MASLD and MetALD: a cohort study","volume":"23","author":"Ichikawa","year":"2025","journal-title":"Biomed Rep"},{"key":"10.1016\/j.clnu.2026.106800_bib46","doi-asserted-by":"crossref","DOI":"10.1186\/s12933-023-01945-x","article-title":"Hepatic steatosis with significant fibrosis is associated with an increased 10-year estimated risk of cardiovascular disease in adults with type 1 diabetes mellitus","volume":"22","author":"Mantovani","year":"2023","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.clnu.2026.106800_bib47","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1007\/s11606-020-06447-0","article-title":"The impact of social determinants of health on medication adherence: a systematic review and meta-analysis","volume":"36","author":"Wilder","year":"2021","journal-title":"J Gen Intern Med"}],"container-title":["Clinical Nutrition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S026156142600227X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S026156142600227X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T00:19:09Z","timestamp":1793233149000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S026156142600227X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":47,"alternative-id":["S026156142600227X"],"URL":"https:\/\/doi.org\/10.1016\/j.clnu.2026.106800","relation":{},"ISSN":["0261-5614"],"issn-type":[{"value":"0261-5614","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A multidisciplinary nutritional-behavioral intervention improves weight loss and liver-related outcomes in patients with metabolic dysfunction-associated steatotic liver disease: A randomized controlled trial","name":"articletitle","label":"Article Title"},{"value":"Clinical Nutrition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clnu.2026.106800","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"106800"}}